SCHEMBL2118620

SCHEMBL2118620

COC(=O)c1ccc2c(=O)[nH]c(CCl)nc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.72
RECQL P46063 1/20 0.72
ALDH1A1 P00352 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
HTT P42858 2/20 0.62
RAB9A P51151 2/20 0.62
HSD17B10 Q99714 3/20 0.57
MAPT P10636 2/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
POLB P06746 1/20 0.56
PARP1 P09874 3/20 0.49
PDE5A O76074 1/20 0.48
TNKS O95271 1/20 0.48
CSNK2A1 P68400 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
USP2 O75604 1/20 0.45
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31483754 1.00 KDM4E (0.72) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL10262840 0.87 KDM4E (0.62) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL2039522 0.85 KDM4E (0.60) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL2118708 0.83 ALDH1A1 (0.58) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL6093891 0.83 SMN1; SMN2 (0.57) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL402452 0.82 PDE5A (0.57) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL2118255 0.81 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2HTTRAB9A
SCHEMBL37938 0.81 PDE5A (0.77) KDM4ERECQLALDH1A1SMN1; SMN2HTT
SCHEMBL24329791 0.80 ALDH1A1 (0.60) KDM4EALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL2117452 0.80 KDM4E (0.54) KDM4ERECQLALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 EP disclosed
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 EP disclosed
EP-3728207-B1 QUINAZOLINONES AS PARP14 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-02-01 EP disclosed
EP-3728207-B1 QUINAZOLINONES AS PARP14 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-02-01 EP disclosed
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2023-01-19 US disclosed
US-11008308-B2 Quinazolinones as PARP14 inhibitors Ribon Therapeutics Inc. (US) 2021-05-18 US disclosed
US-11008308-B2 Quinazolinones as PARP14 inhibitors Ribon Therapeutics Inc. (US) 2021-05-18 US disclosed
EP-3728207-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2020-10-28 EP disclosed
CN-111699176-A Quinazolinones as PARP14 inhibitors 里邦医疗公司 2020-09-22 CN disclosed
US-20200247788-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2020-08-06 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
WO-2012054332-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-26 WO disclosed
WO-2012054332-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-26 WO disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 KDM4E 769/4885RECQL 1493/4885ALDH1A1 298/4885
US-20200247788-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 KDM4E 383/4885RECQL 538/4885ALDH1A1 2388/4885
US-11008308-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 KDM4E 383/4885RECQL 538/4885ALDH1A1 2388/4885
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 KDM4E 769/4885RECQL 1493/4885ALDH1A1 298/4885
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 KDM4E 383/4885RECQL 538/4885ALDH1A1 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.